APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

SIMPLE SUMMARY: Colorectal cancer (CRC) is a major cause of cancer deaths. Cetuximab is an FDA-approved, underutilized therapeutic targeting the epidermal growth factor receptor (EGFR) in metastatic CRC. To date, despite selection of patients with wild-type RAS, it is still difficult to identify pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thota, Ramya, Yang, Mingli, Pflieger, Lance, Schell, Michael J., Rajan, Malini, Davis, Thomas B., Wang, Heiman, Presson, Angela, Pledger, Warren Jack, Yeatman, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582550/
https://www.ncbi.nlm.nih.gov/pubmed/34771559
http://dx.doi.org/10.3390/cancers13215394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582550/
https://www.ncbi.nlm.nih.gov/pubmed/34771559
http://dx.doi.org/10.3390/cancers13215394

Ejemplares similares